IMPORTANCE Surfactant administration by minimally invasive methods that allow for spontaneous breathing might be safer and more effective than administration with endotracheal intubation and mechanical ventilation; however, the efficacy and safety of minimally invasive methods have not been reviewed. OBJECTIVE To conduct a meta-narrative review of the efficacy and safety of minimally invasive...

Administration of endotracheal surfactant is potentially the main treatment for neonates suffering from RDS (Respiratory Distress Syndrome), which is followed by mechanical ventilation. Late and severe complications may develop as a consequence of using mechanical ventilation. In this study, conventional methods for treatment of RDS are compared with surfactant administration, use of mechanical...

BACKGROUND Poractant alfa (Curosurf®) and Bovactant (Alveofact®) are two animal-derived pulmonary surfactants preparations approved for the treatment of neonatal respiratory distress syndrome (nRDS). They differ in their source, composition, pharmaceutical form, and clinical dose. How much these differences affect the acute pulmonary response to treatment is unknown. OBJECTIVES Comparing thes...

OBJECTIVE Our aim was to obtain new information about the relationship between infant responses to surfactant replacement therapy and histopathological changes in vital organs. STUDY DESIGN To accomplish this, the autopsy findings and clinical backgrounds of 41 very low birth weight infants (gestational week 25.6 +/- 2.3; birth weight 806.4 +/- 251.6g) who had died after receiving surfactant ...

BACKGROUND Pulmonary hypoplasia and persistent pulmonary hypertension account for significant mortality and morbidity in neonates with congenital diaphragmatic hernia (CDH). Global lung immaturity and studies in animal models suggest the presence of surfactant deficiency that may further complicate the pathophysiology of CDH. However, data about surfactant status in human fetuses with CDH at bi...

ACUTE RESPIRATORY DISTRESS syndrome (ARDS) was originally termed the adult respiratory distress syndrome because it resembled the clinical picture of infant respiratory distress syndrome (IRDS), and both exhibited hyaline membranes at autopsy. Avery and Mead first reported that lung surfactant quantity and activity were abnormal in infants with IRDS and surfactant replacement has subsequently b...

1975; 39:759 24 Fujiwara T, Childs S, Watabe Y, Macta H, Monta T, et al. Artificial surfactant therapy in hyaline membrane disease. Lancet 1980; 1:55 25 Morley CJ, Miller N, Bangham AD, Davis JA. Dry artificial lung surfactant and its effect on very premature babies. Lancet 1981; 1:64 26 Obladen M, Brendlein F, Krempien B. Surfactant substitution. Eur J Pediatr 1979; 131:219 27 Enhorning C, Gro...

Introduction: Surfactant is an important treatment modality in preterm babies with respiratory distress syndrome leading to decrease mortality, morbidity and cost of treatment. Experiences on surfactant therapy Nepal are scarce. This study was conceptualised find the use immediate outcome a tertiary care hospital Nepal. Methods: A cross-sectional done who received over period five years at neon...